雷公藤多苷治疗肾小球肾炎的有效性与安全性:系统评价与Meta分析
该Meta分析纳入16项对照研究,评估雷公藤多苷(TWP)治疗肾小球肾炎的疗效与安全性。结果显示,加用TWP可改善原发性膜性肾病、2型糖尿病肾病及儿童重症过敏性紫癜性肾炎的缓解率并降低24小时尿蛋白,且未显著增加不良反应。
要点
- TWP加用可提高总缓解率并降低24h尿蛋白和复发事件。
- TWP在总缓解、降低24h尿蛋白及PLA2R转阴方面不劣于糖皮质激素。
- TWP未显著增加不良反应发生率。
核心结论
- TWP对原发性膜性肾病、2型糖尿病肾病及儿童重症过敏性紫癜性肾炎具有治疗获益,且不良反应风险增加有限。
研究设计与样本
- 系统检索PubMed、Cochrane Library、Web of Science和Embase截至2023年7月12日的对照研究,最终纳入16项研究。
主要发现
- 加用TWP改善患者结局和总缓解率,降低24小时尿蛋白并减少复发事件。
- 汇总结果显示TWP在实现总缓解、降低24小时尿蛋白及使PLA2R状态转阴方面不劣于糖皮质激素。
- 对于糖尿病肾病患者,TWP有效降低24小时尿蛋白水平,但未显著改善估算肾小球滤过率(eGFR)。
- 与缬沙坦相比,TWP在降低24小时尿蛋白和eGFR水平方面显示可比改善。
- 儿童重症过敏性紫癜性肾炎加用TWP后观察到显著临床缓解和24小时尿蛋白水平降低。
关键数值与推荐
- 纳入研究涵盖原发性膜性肾病、2型糖尿病肾病和过敏性紫癜性肾炎。
- TWP在总缓解率、24小时尿蛋白降低及PLA2R转阴方面不劣于糖皮质激素。
- TWP未显著增加不良反应发生率。
临床怎么用
- 对于原发性膜性肾病、2型糖尿病肾病及儿童重症过敏性紫癜性肾炎,可考虑在常规治疗基础上加用TWP以改善缓解率并降低蛋白尿。
- TWP可作为糖皮质激素的替代或联合选择之一,但需监测不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of glomerulonephritis presents several challenges, including limited therapeutic options, high costs, and potential adverse reactions. As a recognized Chinese patent medicine, Tripterygium wilfordii poly-glycosides (TWP) have shown promising benefits in managing autoimmune diseases. To evaluate clinical effectiveness and safety of TWP in treating glomerulonephritis, we systematically searched PubMed, Cochrane Library, Web of Science, and Embase databases for controlled studies published up to 12 July 2023. We employed weighted mean difference and relative risk to analyze continuous and dichotomous outcomes. This meta-analysis included 16 studies that included primary membranous nephropathy (PMN), type 2 diabetic kidney disease (DKD), and Henoch-Schönlein purpura nephritis (HSPN). Analysis revealed that additional TWP administration improved patients' outcomes and total remission rates, reduced 24-h urine protein (24hUP) and decreased relapse events. The pooled results demonstrated the non-inferiority of TWP to glucocorticoids in achieving total remission, reducing 24hUP, and converting the phospholipase A2 receptor (PLA2R) status to negative. For DKD patients, TWP effectively reduced 24hUP levels, although it did not significantly improve the estimated glomerular filtration rate (eGFR). Compared to valsartan, TWP showed comparable improvements in 24hUP and eGFR levels. In severe cases of HSPN in children, significant clinical remission and a reduction in 24hUP levels were observed with the addition of TWP treatment. TWP did not significantly increase the incidence of adverse reactions. Therefore, TWP could offer therapeutic benefits to patients with PMN, DKD, and severe HSPN, with a minimal increase in the risk of side effects.
引用
- Yan X, Shi J, Zhang Y, et al. Effectiveness and safety of tripterygium wilfordii poly-glycosides on glomerulonephritis: a systematic review and meta-analysis. Front Pharmacol. 2024. PMID: 38841368. doi:10.3389/fphar.2024.1339153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。